Preview Mode Links will not work in preview mode

Feb 13, 2020

Genomic Assays in the “Real” Oncology World — Part 2: Genomic Assays in Prostate and Breast Cancer — Featuring a roundtable discussion with Drs Emmanuel S Antonarakis, Johanna Bendell, Ian E Krop and Andrew McKenzie.

  • NGS for Metastatic Prostate Cancer (mPC) and the Potential Clinical Significance of Genomic Alterations
  • Genetic alterations assessed in routine practice, including MSI status, BRCA mutations and AR-V7 variants; role of multiplex testing
  • Presentation (Dr Antonarakis): Biomarker assessment in mPC; detection of DNA damage repair abnormalities and prediction of benefit with PARP and PD-1 inhibitors
  • Landscape of DNA damage repair mutations in newly diagnosed and metastatic prostate cancer
  • Rationale for the use of PARP inhibitors for prostate cancer with BRCA or ATM mutations
  • Genetic testing of primary and metastatic tumors for alterations in the DNA repair and androgen receptor (AR) signaling pathways
  • Clinical significance and genetic detection of AR splice variants
  • Results of the CARD trial: Cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experience rapid disease progression on an AR-targeted agent
  • Efficacy of olaparib for mCRPC
  • Available data with rucaparib, niraparib and talazoparib for mCRPC
  • Role of radium-223 dichloride for patients with mPC; novel combination approaches with radium-223 under investigation
  • Sensitivity of BRCA1, BRCA2 and ATM mutations to PARP inhibitors
  • Activity of PARP inhibitors in patients with breast, ovarian, prostate and pancreatic cancers with BRCA mutations
  • Homologous recombination deficiency and response to PARP inhibitors
  • Case (Dr Antonarakis): A man in his mid-40s with mCRPC and a BRCA2 mutation attains a complete response to olaparib
  • Case (Dr Antonarakis): A man in his mid-60s diagnosed with de novo mPC and MSI-high status, high tumor mutation burden and an MSH2 mutation experiences an excellent response to pembrolizumab after multiple lines of therapy
  • Association of ductal and intraductal prostate cancer with a high prevalence of DNA damage repair gene mutations
  • Predictors of benefit with immune checkpoint inhibitors
  • Multigene Testing and Detection of Genomic Alterations in Metastatic Breast Cancer (mBC)
  • Role of MSI testing and multiplex genomic assays in mBC
  • Assessment of PIK3CA and BRCA mutations and assays for ESR1
  • Presentation (Dr Krop): Biomarker assessment in mBC — ER-positive and triple-negative disease
  • PTEN loss and implications for therapeutic decision-making for mBC
  • ESR1 mutations and resistance to hormone therapy
  • Efficacy of PARP inhibitors in patients with BRCA mutations
  • HER2 expression in HER2 nonamplified cancers; activity of trastuzumab deruxtecan in HER2-low breast cancer
  • PD-L1 and other biomarkers predictive of benefit from immunotherapy in triple-negative breast cancer (TNBC)
  • Case (Dr Krop): A woman in her late 50s with de novo TNBC receives atezolizumab/nab paclitaxel as first-line therapy
  • Case (Dr Krop): A woman in her early 60s with ER-positive, HER2-negative mBC and a germline BRCA2 mutation whose disease progresses through multiple therapies attains a partial response to olaparib
  • The Sarah Cannon Experience with Molecular Tumor Boards
  • The use of molecular tumor boards to review molecular profiling data and facilitate therapeutic decision-making

CME information and select publications